Ad Header



The Pulse of the Pharmaceutical Industry

Gilead’s HIV drug gets closer to getting Europe approval

Written by: | | Dated: Friday, February 26th, 2016

Gilead Sciences Inc’s experimental cocktail to treat HIV received a green light from European regulators on Friday, boosting the chances of the drug being formally approved by the European Commission.

The European Medicines Agency issued a positive opinion on the treatment, Descovy, a combination of emtricitabine and tenofovir alafenamide. Both drugs stop HIV from multiplying.

The company is awaiting an approval from the U.S. Food and Drug Administration.

One of Gilead’s treatments for HIV, Truvada, is an approved drug to be taken in a PrEP regimen, a group of drugs recommended by the U.S. Centers for Disease Control and Prevention to help prevent HIV infection.

Gilead’s shares rose about 1 percent to $90.89 in light premarket trading on Friday.

Europe’s drug regulator also recommended approving hemophilia treatments from Biogen Inc and CSL Ltd as well as Eli Lilly & Co’s psoriasis treatment. (

Eli Lilly’s experimental drug, ixekizumab, belongs to a new class of psoriasis treatments called IL-17 receptor antagonists. The drug will compete directly with Novartis AG’s newly approved Cosentyx.



(Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D’Souza and Saumyadeb Chakrabarty)

Source: Reuters Health

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation